Pfizer and Schlumberger Are January Bounce Candidates
Morgan Stanley Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Sticks to Their Hold Rating for Pfizer (PFE)
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Express News | Shenzhen Kangtai Biological Products: The 20-valent pneumococcal polysaccharide conjugate vaccine has initiated phase I clinical trials.
Hong Kong stocks fluctuate | zai lab (09688) rises over 5% as it reaches a collaboration in mainland china with pfizer on a new antibacterial drug.
zai lab (09688) rose more than 5%, as of the deadline, up 5.26%, trading at 20.8 Hong Kong dollars, with a turnover of 7.8692 million Hong Kong dollars.